Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Kisqali ® (ribociclib) is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). Femara is an aromatase inhibitor approved for first-line treatment of postmenopausal women with HR-positive or unknown advanced breast cancer. Kisqali was approved on 13 March, 2017 in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with HR-positive/HER2-negative advanced or metastatic breast cancer. The Kisqali Femara co-pack will be available in the US later this month at both specialty and retail pharmacies, and does not change the indication for either medicine.
Kisqali side effect plus#
The Kisqali Femara co-pack is available in three dosage strengths: Kisqali 600 mg plus Femara 2.5 mg, Kisqali 400 mg plus Femara 2.5 mg, and Kisqali 200 mg plus Femara 2.5 mg. The Kisqali Femara co-pack is available at the same cost as Kisqali alone.
Kisqali side effect full#
The innovative packaging of the Kisqali Femara co-pack allows patients the convenience of obtaining a full 28-day cycle of the two medicines in one package with one prescription and one co-pay. With this FDA approval, physicians in the United States now have the flexibility to prescribe Kisqali two different ways: via the new co-pack or as two separate prescriptions of Kisqali and any aromatase inhibitor.
It is the first co-pack, and only currently available, combination pack with two prescription products in advanced breast cancer. On 8 May, 2017 Novartis announced that the US Food and Drug Administration (FDA) has approved the ribociclib (Kisqali ®)- letrozole (Femara ®) co-pack (ribociclib tablets letrozole tablets) for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER-2)-negative advanced or metastatic breast cancer in postmenopausal women.
0 kommentar(er)
